(3,4-dimethoxy-benzyl)-(2-(furan-2-yl)-8-methyl-pyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl)amine | 1410219-69-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,4-dimethoxy-benzyl)-(2-(furan-2-yl)-8-methyl-pyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl)amine
• 英文别名: N-[(3,4-dimethoxyphenyl)methyl]-4-(furan-2-yl)-11-methyl-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaen-7-amine
• CAS: 1410219-69-0
• 化学式: C₂₀H₁₉N₇O₃
• 分子量: 405.416
• InChiKey: MWVVPKMOFGWWBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-[3-(2-furyl)-1H-1,2,4-triazol-5-yl]-1-methyl-1H-pyrazol-3-amine 在 吡啶 、 五氯化磷 、 三乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 27.5h， 生成 (3,4-dimethoxy-benzyl)-(2-(furan-2-yl)-8-methyl-pyrazolo-[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl)amine
  参考文献：
  名称：

  Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A_2A Adenosine Receptor Antagonists

  摘要：

  The application of both structure- and ligand-based design approaches represents to date one of the most useful strategies in the discovery of new drug candidates. In the present paper, we investigated how the application of docking-driven conformational analysis can improve the predictive ability of 3D-QSAR statistical models. With the use of the crystallographic structure in complex with the high affinity antagonist ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]-triazolo [2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol), we revisited a general pharmacophore hypothesis for the human A(2A) adenosine receptor of a set of 751 known antagonists, by applying an integrated ligand- and structure-based approach. Our novel pharmacophore hypothesis has been validated by using an external test set of 29 newly synthesized human adenosine receptor antagonists.

  DOI：

  10.1021/ci300615u

文献信息

• Revisiting a Receptor-Based Pharmacophore Hypothesis for Human A_2A Adenosine Receptor Antagonists
  作者：Magdalena Bacilieri、Antonella Ciancetta、Silvia Paoletta、Stephanie Federico、Sandro Cosconati、Barbara Cacciari、Sabrina Taliani、Federico Da Settimo、Ettore Novellino、Karl Norbert Klotz、Giampiero Spalluto、Stefano Moro

  DOI：10.1021/ci300615u

  日期：2013.7.22

  The application of both structure- and ligand-based design approaches represents to date one of the most useful strategies in the discovery of new drug candidates. In the present paper, we investigated how the application of docking-driven conformational analysis can improve the predictive ability of 3D-QSAR statistical models. With the use of the crystallographic structure in complex with the high affinity antagonist ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]-triazolo [2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol), we revisited a general pharmacophore hypothesis for the human A(2A) adenosine receptor of a set of 751 known antagonists, by applying an integrated ligand- and structure-based approach. Our novel pharmacophore hypothesis has been validated by using an external test set of 29 newly synthesized human adenosine receptor antagonists.